Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Jill Maaske, Stephanie Sproule, Ann R Falsey, Magdalena E Sobieszczyk, Anne F Luetkemeyer, Grant C Paulsen, Sharon A Riddler, Merlin L Robb, Charlotte-Paige Rolle, Beverly E Sha, Tina Tong, Bahar Ahani, Anastasia A Aksyuk, Himanshu Bansal, Timothy Egan, Brett Jepson, Marcelino Padilla, Nirmeshkumar Patel, Kathryn Shoemaker, Ann Marie Stanley, Phillip A Swanson, Deidre Wilkins, Tonya Villafana, Justin A Green, Elizabeth J Kelly
Front Immunol 13 1062067
摘要
摘要
BACKGROUND: Breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in coronavirus disease 2019 (COVID-19) vaccinees typically produces milder disease than infection in unvaccinated individuals. METHODS: To explore disease attenuation, we examined COVID-19 symptom burden and immuno-virologic responses to symptomatic SARS-CoV-2 infection in participants (AZD1222: n=177/17,617; placebo: n=203/8,528) from a 2:1 randomized, placebo-controlled, phase 3 study of two-dose primary series AZD1222 (ChAdOx1 nCoV-19) vaccination (NCT04516746). RESULTS: We observed that AZD1222 vaccinees had an overall lower incidence and shorter duration of COVID-19 symptoms compared with placebo recipients, as well as lower SARS-CoV-2 viral loads and a shorter median duration of viral shedding in saliva. Vaccinees demonstrated a robust antibody recall response versus placebo recipients with low-to-moderate inverse correlations with virologic endpoints. Vaccinees also demonstrated an enriched polyfunctional spike-specific Th-1-biased CD4+ and CD8+ T-cell response that was associated with strong inverse correlations with virologic endpoints. CONCLUSION: Robust immune responses following AZD1222 vaccination attenuate COVID-19 disease severity and restrict SARS-CoV-2 transmission potential by reducing viral loads and the duration of viral shedding in saliva. Collectively, these analyses underscore the essential role of vaccination in mitigating the COVID-19 pandemic.
KM 提取结果
0 个 Figure · 0 个 KM 面板